ReGenesys

FlandersBio on Twitter

Galapagos NV: business update: http://t.co/6w1jppWE

posted 5 days ago

Social Media

Life Sciences Database

in het nederlands

FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.

Website: http://www.regenesys.be
Email:
Phone: +32 16 75 13 55
FlandersBio Member
More address details

Business Focus

ReGenesys is a biopharmaceutical company focused on the research and development of stem cell based therapies. ReGenesys is a wholly-owned subsidiary of Athersys, a publicly held biotechnology company located in Cleveland, Ohio.

Company Profile

ReGenesys is a wholly-owned subsidiary of Athersys, a publicly held biotechnology company located in Cleveland, Ohio (NASDAQ: ATHX). The company has two core business units. One is based on drug discovery / functional genomics screening, and has developed a lead compound for treatment of obesity that is now in Phase II clinical study. The second platform is a stem cell therapeutic opportunity, based on pluripotent stem cells isolated from bone marrow. The company has established master cell banks and successfully produced a cGMP cell product by FDA guidelines. ReGenesys is focused on establishing additional stem cell banks and European manufacturing capability.

Science & Technology or Services

The company's stem cell product, MultiStem™, is a cryopreserved allogeneic cell product. Currently, a Phase I clinical trial on AMI has been executed and 2 trials are open; one for the treatment of graft versus host disease (aGVHD) in bone marrow transplantation, one for treatment of Stroke.

The company is planning new trials for cGVHD, support in organ transplantation and inflammatory bowel diseases.

Products
MultiStem™ – a cryopreserved allogeneic cell product
Regenerative medicine (AMI/GVDH/Stroke)
Phase I/II

Alliances

ReGenesys/Athersys have allied with Pfizer for inflammatory bowel diseases and with Angiotech for AMI.
ReGenesys/Athersys are currently working with Lonza (Walkersville, US and Verviers, Belgium) for clinical cell dose production.
ReGenesys is working with FertiPro (Beernem, Belgium) for new media development.